SEC Form 4
Quoin Pharmaceuticals, Ltd. (QNRX) insider trading
In the 12 months to Oct 26, 2026, 4 QNRX insiders reported open-market purchases of $280.0K across 4 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $280.0K
- 4 filings
Who traded QNRX, and when
- Purchase
QNRX daily close from Oct 27, 2025 to Oct 26, 2026, between $3.25 and $22.30, last $4.08. 0 sale and 4 purchase filings by 4 insiders, marked at their filing dates. Denise P. Carter, Chief Operating Officer: bought $100.0K across 1 filing, first filed Sep 1, 2026, last Sep 1, 2026. Michael Myers, Chief Executive Officer: bought $100.0K across 1 filing, first filed Sep 1, 2026, last Sep 1, 2026. Sally Bridget Lawlor, Chief Financial Officer: bought $50.0K across 1 filing, first filed Sep 1, 2026, last Sep 1, 2026. Anthony James Culverwell, Director: bought $30.0K across 1 filing, first filed Sep 1, 2026, last Sep 1, 2026.
Largest mark · tap a row for others
Denise P. Carter · Chief Operating Officer
Purchase $99,991
20,490 ADS at $4.88 avg
Filed Sep 1, 2026 · traded Aug 31
Close on filing date $6.51
Denise P. Carter · Chief Operating Officer
Chief Operating Officer
$100.0K boughtMichael Myers · Chief Executive Officer
Chief Executive Officer
$100.0K boughtSally Bridget Lawlor · Chief Financial Officer
Chief Financial Officer
$50.0K boughtAnthony James Culverwell · Director
Director
$30.0K boughtOpen-market trades
4 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Denise P. Carter | Chief Operating Officer | — | $100.0K | 1 | — | |
| Michael Myers | Chief Executive Officer | — | $100.0K | 1 | — | |
| Sally Bridget Lawlor | Chief Financial Officer | — | $50.0K | 1 | — | |
| Anthony James Culverwell | Director | — | $30.0K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Anthony James Culverwell Director | Purchase | 6,146 | $4.88 | $30.0K | 40,364 | |
traded | Sally Bridget Lawlor Chief Financial Officer | Purchase | 10,244 | $4.88 | $50.0K | 10,684 | |
traded | Michael Myers Chief Executive Officer | Purchase | 20,490 | $4.88 | $100.0K | 37,713 | |
traded | Denise P. Carter Chief Operating Officer | Purchase | 20,490 | $4.88 | $100.0K | 37,709 |
GET /stocks/filings/vX/form-4?tickers=QNRX&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"QNRX"
],
"issuer_cik": "0001671502",
"owner_cik": "0001959547",
"accession_number": "0001104659-26-104404",
"form_type": "4",
"filing_date": "2026-09-01",
"period_of_report": "2026-08-31",
"issuer_name": "Quoin Pharmaceuticals, Ltd.",
"issuer_trading_symbol": "QNRX",
"owner_name": "Myers Michael",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "ADSs",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-31",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 20490,
"transaction_price_per_share": 4.88,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 37713,
"transaction_value": 99991.2,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Ordinary Shares are represented by American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five (35) ordinary shares of the Issuer."
},
{
"id": "F2",
"description": "Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."
}
]
},
{
"tickers": [
"QNRX"
],
"issuer_cik": "0001671502",
"owner_cik": "0001693548",
"accession_number": "0001104659-26-104402",
"form_type": "4",
"filing_date": "2026-09-01",
"period_of_report": "2026-08-31",
"issuer_name": "Quoin Pharmaceuticals, Ltd.",
"issuer_trading_symbol": "QNRX",
"owner_name": "Culverwell Anthony James",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "ADSs",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-31",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 6146,
"transaction_price_per_share": 4.88,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 40364,
"transaction_value": 29992.48,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Ordinary Shares are represented by American Depositary Shares (\"ADSs\"). Each ADS represents thirty-five (35) ordinary shares of the Issuer."
},
{
"id": "F2",
"description": "Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants (\"Warrants\") were issued at a combined purchase price of $4.88."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 2 records
- Grants and awards2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Quoin Pharmaceuticals, Ltd.'s CEO sold stock?
No. Michael Myers (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is QNRX’s insider data?
These are QNRX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track QNRX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for QNRX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.